Home
About
Overview
Sharing Data
ORCID
Help
History (0)
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Rubin, David T.
One or more keywords matched the following items that are connected to
Rubin, David T.
Item Type
Name
Concept
Mesalamine
Academic Article
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
Academic Article
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
Academic Article
Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.
Academic Article
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Academic Article
Will a 5-ASA a day keep the cancer (and dysplasia) away?
Academic Article
Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide.
Academic Article
What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis.
Academic Article
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.
Academic Article
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Academic Article
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
Academic Article
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
Academic Article
Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
Academic Article
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Academic Article
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.
Academic Article
Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
Academic Article
ACG Clinical Guideline: Ulcerative Colitis in Adults.
Academic Article
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
Academic Article
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
Academic Article
Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD.
Search Criteria
Mesalamine